TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 740nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 830nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 944nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 998nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.00E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.00E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.01E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.02E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.02E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.03E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.04E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.06E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.06E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.07E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.13E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.13E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.14E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.17E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.17E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.19E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.20E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.23E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.26E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.29E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.35E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.41E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.43E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.44E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.45E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.46E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.47E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.50E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.51E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.54E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.54E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.54E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.55E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.59E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.61E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.65E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.77E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.78E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.78E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 2.00E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 2.08E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 2.19E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 2.32E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 2.68E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 2.74E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 2.75E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair